G004431

LC/MS Analysis of Clenbuterol In Plasma on Astec^® CHIROBIOTIC^® T with Phospholipid Removal using HybridSPE^® Phospholipid

application for SPE, application for LC-MS

Eigenschaften

• Methode(n): LC/MS: suitable; solid phase extraction (SPE): suitable
• Testparameter: sample preparation: SPE (Solid Phase Extraction); sample/matrix: rat plasma spiked with clenbuterol enantiomers at 10 ng/mL; SPE well plate: HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U); sample addition: 100 μL spiked rat plasma followed by 300 μL 1% formic acid in acetonitrile. Mix by vortexing the HybridSPE-PPT plate briefly.; elution: apply vacuum; column: CHIROBIOTIC T, 10 cm x 2.1 mm I.D., 5 μm particles (12018AST); mobile phase: 10 mM ammonium formate in methanol; flow rate: 0.3 mL/min; column temp.: 30 °C; detector: ABI 3200 QT; ESI(+), MRM: 184/104 m/z (phospholipids); 277.2/203.1 m/z (clenbuterol); injection: 10 μL
• Eignung: application for LC-MS; application for SPE
• Anwendung(en): clinical; forensics and toxicology; pharmaceutical (small molecule)

Beschreibung

Anwendung

The HybridSPE method provides significant improvement in LC-MS baseline.

Rechtliche Hinweise

Astec is a registered trademark of Merck KGaA, Darmstadt, Germany

CHIROBIOTIC is a registered trademark of Sigma-Aldrich Co. LLC

HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany